[1]MUOZ-GALVNS,CARNERO A.Targeting cancer stem cells to overcome therapy resistance in ovarian cancer[J].Cells,2020,9(6):1402-1425.
[2]ZHANG R,SIU MKY,NGAN HYS,et al.Molecular biomarkers for the early detection of ovarian cancer[J].Int J Mol Sci,2022,23(19):12041-12057.
[3]TIAN W,LEI N,ZHOU J,et al.Extracellular vesicles in ovarian cancer chemoresistance,metastasis,and immune evasion[J].Cell Death Dis,2022,13(1):64-76.
[4]WEI X,LYU H,YANG S,et al.CircRNA PLOD2 enhances ovarian cancer propagation by controlling miR-378[J].Saudi J Biol Sci,2021,28(11):6260-6265.
[5]ZHENG J,YAN X,LU T,et al.CircFOXK2 promotes hepatocellular carcinoma progression and leads to a poor clinical prognosis via regulating the Warburg effect[J].J Exp Clin Cancer Res,2023,42(1):63-84.
[6]ZHANG W,LIU H,JIANG J,et al.CircRNA circFOXK2 facilitates oncogenesis in breast cancer via IGF2BP3/miR-370 axis[J].Aging(Albany NY),2021,13(14):18978-18992.
[7]ASL ER,SARABANDI S,SHADEMAN B,et al.MicroRNA targeting:A novel therapeutic intervention for ovarian cancer[J].Biochem Biophys Rep,2023,35:101519.
[8]FU X,ZHANG L,DAN L,et al.LncRNA EWSAT1 promotes ovarian cancer progression through targeting miR-330-5p expression[J].Am J Transl Res,2017,9(9):4094-4103.
[9]MA H,QU S,ZHAI Y,et al.circ_0025033 promotes ovarian cancer development via regulating the hsa_miR-370-3p/SLC1A5 axis[J].Cell Mol Biol Lett,2022,27(1):94-108.
[10]WANG K,GUAN C,SHANG X,et al.A bioinformatic analysis:The overexpression and clinical significance of FCGBP in ovarian cancer[J].Aging(Albany NY),2021,13(5):7416-7429.
[11]CHANDRA A,PIUS C,NABEEL M,et al.Ovarian cancer:Current status and strategies for improving therapeutic outcomes[J].Cancer Med,2019,8(16):7018-7031.
[12]GENG Y,WANG M,WU Z,et al.Research progress of circRNA in malignant tumour metabolic reprogramming[J].RNA Biol,2023,20(1):641-651.
[13]XU Q,DENG B,LI M,et al.circRNA-UBAP2 promotes the proliferation and inhibits apoptosis of ovarian cancer though miR-382-5p/PRPF8 axis[J].J Ovarian Res,2020,13(1):81-91.
[14]ZHANG Y,WANG Y,ZHAO G,et al.FOXK2 promotes ovarian cancer stemness by regulating the unfolded protein response pathway[J].J Clin Invest,2022,132(10):1-16.
[15]ZHANG N,FAN J,DENG Z.CircFOXK2 enhances tumorigenesis and immune evasion in non-small cell lung cancer by miR-485-5p/PD-L1 axis[J].Anticancer Drugs,2022,33(5):437-447.
[16]VERDUCI L,STRANO S,YARDEN Y,et al.The circRNA-microRNA code:Emerging implications for cancer diagnosis and treatment[J].Mol Oncol,2019,13(4):669-680.
[17]MENON A,ABD-AZIZ N,KHALID K,et al.miRNA:A promising therapeutic target in cancer[J].Int J Mol Sci,2022,23(19):11502-11531.
[18]QIN L,SUN X,ZHOU F,et al.CircLRP6 contributes to prostate cancer growth and metastasis by binding to miR-330-5p to up-regulate NRBP1[J].World J Surg Oncol,2021,19(1):184-198.
[19]XU S,LEI SL,LIU KJ,et al.circSFMBT1 promotes pancreatic cancer growth and metastasis via targeting miR-330-5p/PAK1 axis[J].Cancer Gene Ther,2021,28(3-4):234-249.
[20]HAN L,ZHOU J,LI L,et al.SLC1A5 enhances malignant phenotypes through modulating ferroptosis status and immune microenvironment in glioma[J].Cell Death Dis,2022,13(12):1071-1085.
[21]LUO H,PENG J,YUAN Y.CircRNA OXCT1 promotes the malignant progression and glutamine metabolism of non-small cell lung cancer by absorbing miR-516b-5p and upregulating SLC1A5[J].Cell Cycle,2023,22(10):1182-1195.